GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

Home・Listă Acțiuni・Camurus AB

Camurus AB

Închisă

723.5 -0.07

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

716

Maxim

730

Indicatori cheie
By Trading Economics
Venit	53M 292M
Vânzări	117M 676M
P/E Medie Sector	59.883 35.733
EPS	4.08
Marjă de profit	43.235
Angajați	267
EBITDA	54M 315M

Statistici piață
By TradingEconomics
Capitalizare de piață	1.8B 43B
Deschiderea anterioară	723.57
Închiderea anterioară	723.5

Camurus AB Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 sept. 2025, 16:09 UTC

Achiziții, Fuziuni, Preluări

BBVA Clears Last Hurdle to Open $17.4 Billion Bid to Sabadell Shareholders -- 2nd Update

5 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 20:37 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 sept. 2025, 20:37 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 sept. 2025, 20:36 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 sept. 2025, 20:36 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 sept. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 sept. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 sept. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 sept. 2025, 20:20 UTC

Câștiguri

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 sept. 2025, 19:22 UTC

Câștiguri

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 sept. 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 sept. 2025, 18:59 UTC

Câștiguri

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 sept. 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 sept. 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 sept. 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 sept. 2025, 16:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Global Energy Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 sept. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 16:16 UTC

Câștiguri

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

5 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Camurus AB Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.